ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Palliative and end-of-life care · Support Care Cancer · 2026-08-05

Meta-analysis of 43 studies of neoadjuvant/adjuvant immune checkpoint inhibitors: fatigue was more frequent than with placebo (RR 1.21, 95% CI 1.08-1.35), with slightly higher patient-reported fatigue; no significant difference versus chemotherapy. Risk of bias was high.

Meta-analysisn = 43 studies
Potter et al. Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis
Oncology · Cancer Treat Rev · 2026-06-25

Meta-analysis of 9 studies (2,564 patients) of MSI-H/dMMR metastatic colorectal cancer on checkpoint inhibitors: response rates did not differ by mutation, but BRAF-mutated tumours had shorter PFS (HR 1.37) and OS (HR 1.74); RAS-mutated had modestly longer PFS (HR 0.81).

Meta-analysisn = 2,564
Pretta et al. Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Oncology · Eur J Cancer · 2026-05-25

Living systematic review of 41 RCTs (15,049 patients) in solid tumours: adding checkpoint inhibitors to radiotherapy did not significantly improve OS (HR 0.88, 95% CI 0.75–1.02; 28 trials), but did excluding glioblastoma (HR 0.83); PFS HR 0.80, EFS HR 0.73.

Meta-analysisn = 15,049
Tomassen et al. The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials
Rheumatology · Semin Arthritis Rheum · 2026-01-31

Meta-analysis of 31 studies (over 700 patients with solid tumours and pre-existing rheumatologic disease) on immune checkpoint inhibitors: pooled flare incidence was 33.8% (grade 3-5: 4.2%), median onset 38.5 days, varying from 3.8% in SLE to 46.4% in psoriatic arthritis.

Meta-analysisn = 31 studies
Yamada et al. Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.